Insilico Medicine signed a multiyear R&D collaboration with Servier valued at up to $888 million to apply Insilico’s AI discovery platform to oncology targets. The agreement includes up‑front and near‑term payments and an arrangement for Servier to lead clinical validation and commercialization of candidates. Media reports and regulatory filings add that the partnership aims to accelerate candidate identification and reduce early‑stage attrition through AI‑driven target selection and chemistry.